STOCK TITAN

Ligand Pharma Stock Price, News & Analysis

LGNYZ OTC Link

Company Description

Ligand Pharma (OTC Link: LGNYZ) is a publicly traded company.

LGNYZ stock has gained 70.9% over the past year. Shares last traded at $0.0600.

On a trailing twelve-month basis, Ligand Pharma reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.

This page provides a comprehensive overview of LGNYZ stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

$—
0.00%
0.00
Last updated:
+70.94%
Performance 1 year

Ligand Pharma (LGNYZ) stock last traded at $0.0600. Over the past 12 months, the stock has gained 70.9%.

LGNYZ Rankings

Latest News

No recent news available for LGNYZ.

SEC Filings

Ligand Pharma has filed 10 recent SEC filings, including 4 Form 144, 2 Form 4, 2 Form 10-Q, 2 Form 8-K. The most recent filing was submitted on May 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNYZ SEC filings →

Financial Highlights

Ligand Pharma generated $268.1M in revenue over the trailing twelve months, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. With a current ratio of 22.23, the balance sheet reflects a strong liquidity position.

$268.1M
Revenue (TTM)
$124.5M
Net Income (TTM)
$49.4M
Operating Cash Flow

Upcoming Events

Short Interest History

Last 12 Months

Short interest in Ligand Pharma (LGNYZ) currently stands at 9.1 thousand shares, down 2.4% from the previous reporting period. Over the past 12 months, short interest has increased by 36.1%. With 202.2 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.

Days to Cover History

Last 12 Months

Days to cover for Ligand Pharma (LGNYZ) currently stands at 202.2 days, up 20120% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 20120% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.

Frequently Asked Questions

What is the current stock price of Ligand Pharma (LGNYZ)?

The current stock price of Ligand Pharma (LGNYZ) is $0.06 as of May 12, 2026.

What is the revenue (TTM) of Ligand Pharma (LGNYZ) stock?

The trailing twelve months (TTM) revenue of Ligand Pharma (LGNYZ) is $268.1M.

What is the net income of Ligand Pharma (LGNYZ)?

The trailing twelve months (TTM) net income of Ligand Pharma (LGNYZ) is $124.5M.

What is the earnings per share (EPS) of Ligand Pharma (LGNYZ)?

The diluted earnings per share (EPS) of Ligand Pharma (LGNYZ) is $6.13 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Ligand Pharma (LGNYZ)?

The operating cash flow of Ligand Pharma (LGNYZ) is $49.4M. Learn about cash flow.

What is the profit margin of Ligand Pharma (LGNYZ)?

The net profit margin of Ligand Pharma (LGNYZ) is 46.4%. Learn about profit margins.

What is the operating margin of Ligand Pharma (LGNYZ)?

The operating profit margin of Ligand Pharma (LGNYZ) is 15.3%. Learn about operating margins.

What is the current ratio of Ligand Pharma (LGNYZ)?

The current ratio of Ligand Pharma (LGNYZ) is 22.23, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of Ligand Pharma (LGNYZ)?

The operating income of Ligand Pharma (LGNYZ) is $41.0M. Learn about operating income.